Molecular Drug Targets-1
-
Upload
phoebe-llamelo -
Category
Documents
-
view
223 -
download
0
Transcript of Molecular Drug Targets-1
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 1/75
“Corpora non agunt nisi fixata”
Compounds do not act unless bound
Paul Ehrlich 1854-1915
-Dr Alicia Catabay
-Department of Pharmaceutical Chemistry
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 2/75
IntroductionTargets are molecular structures, chemically definable by at
least a molecular mass, that will undergo a specificinteraction with chemicals that we call drugs because they
are administered to treat or diagnose a disease. A clinically relevant target might consist not of a single
biochemical entity, but the simultaneous interference of a
number of receptors.
Only this will give a net clinical effect that might beconsidered beneficial.
It is only by chance that the current in vitro screeningtechniques will identify drugs that work through suchtargets.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 4/75
The problem with counting is mainly 2-fold:
1. the identification of the reaction partners of drugsubstances in the body, and
2. exactly what to define and count as the target.
A target definition derived from the net effect ratherthan the direct chemical interaction will require inputfrom systems biology, a nascent research field that
promises to affect the drug discovery processsignificantly.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 5/75
Mechanisms of action An effective drug target comprises a biochemical system
rather than a single molecule.
Present target definitions are static. We know this to beinsufficient, but techniques to observe the dynamics of drug–target interactions are just being created.
Most importantly, we are not able to gauge the
interaction of the biochemical “ ripples” that followthe drug’s initial molecular effect.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 6/75
It has been pointed out that “ two components areimportant to the mechanism of action …
The first component is the initial mass-action-dependent interaction …
The second component requires a coupled biochemicalevent to create a transition away from mass-actionequilibrium ” and “ drug mechanisms that createtransitions to a non-equilibrium state will be moreefficient. ”
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 7/75
Although the term “ mechanism of action ” itself implies a classification according to the dynamics of drug
substance effects at the molecular level, the dynamicsof these interactions are only speculative models at
present, and so mechanism of action can currently only be used to describe static targets.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 8/75
Drug targets
Most drug targets are cellular proteins
-undergoing selective interaction with drugs
to treat or diagnose a disease-are human-genome-derived proteins
-or may belong to bacterial, viral, fungal or otherpathogenic organisms
What is a human genome?
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 9/75
Human genome project The Human Genome Project (HGP) is an international
scientific research project with a primary goal of determining the sequence of chemical base pairs whichmake up DNA and of identifying and mapping the
approximately 20,000–25,000 genes of the human genomefrom both a physical and functional standpoint
Human genome is the genome of Homo sapiens, which isstored on 23 chromosome pairs plus the smallmitochondrial DNA
22 of the 23 chromosomes are autosomal chromosomepairs, while the remaining pair is sex-determining.
The haploid human genome occupies a total of just over 3billion DNA base pairs.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 10/75
The human genome, categorized by function of each gene product, given both
as number of genes and percentage of all genes.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 11/75
Key findings of the draft (2001) and complete (2004)genome sequences include :
1. There are approximately 30,000 genes in human beings, thesame range as in mice and twice that of roundworms.Understanding how these genes express themselves willprovide clues to how diseases are caused.[
2. Between 1.1% to 1.4% of the genome's sequence codes for
proteins3. The human genome has significantly more segmental
duplications (nearly identical, repeated sections of DNA)than other mammalian genomes.
These sections may underlie the creation of new primate-
specific genes4. At the time when the draft sequence was published less
than 7% of protein families appeared to be vertebratespecific
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 12/75
The Human Genome Project is considered a mega
project because the human genome has approximately 3.3 billion base-pairs.
If the sequence obtained was to be stored in bookform, and if each page contained 1000 base-pairsrecorded and each book contained 1000 pages, then3300 such books would be needed in order to store thecomplete genome.
However, if expressed in units of computer datastorage, 3.3 billion base-pairs recorded at 2 bits perpair would equal 786 megabytes of raw data. This iscomparable to a fully data loaded CD.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 13/75
Benefits of the project
The work on interpretation of genome data is still in its initialstages. It is anticipated that detailed knowledge of the humangenome will provide new avenues for advances in medicine andbiotechnology.
Clear practical results of the project emerged even before the work was finished.
For example, a number of companies, started offering easy ways toadminister genetic tests that can show predisposition to a variety of illnesses, including breast cancer, hemostasis disorders, cysticfibrosis liver diseases and many others.
Also, the etiologies for cancers, Alzheimer’s disease and other areasof clinical interest are considered likely to benefit from genomeinformation and possibly may lead in the long term to significantadvances in their management.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 14/75
There are also many tangible benefits for biological
scientists.For example, a researcher investigating a certain form
of cancer may have narrowed down his/her search to aparticular gene.
By visiting the human genome database on the WWW the researcher can examine what other scientists have written about this gene, including three-dimensionalstructure of its product, its function, its evolutionary relationships to other human genes, or to genes inmice or yeast or fruit flies, possible detrimentalmutations, interactions with other genes, body tissuesin which this gene is activated, diseases associated with this gene or other datatypes.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 15/75
Further, deeper understanding of the disease processesat the level of molecular biology may determine newtherapeutic procedures.
Given the established importance of DNA in
molecular biology and its central role in determiningthe fundamental operation of cellular processes, it islikely that expanded knowledge in this area willfacilitate medical advances in numerous areas of
clinical interest that may not have been possible without them.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 16/75
Advantages of Human Genome Project:
Knowledge of the effects of variation of DNA amongindividuals can revolutionize the ways to diagnose,treat and even prevent a number of diseases thataffects the human beings.
It provides clues to the understanding of humanbiology.
Access to the complete human genome sequence as well as to the complete sequences of pathogenicorganisms provides information that can result in anavalanche of therapeutic targets.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 17/75
The alternative method of rational drug designinvolves the design and synthesis of compounds basedon the known structure of either a specific target orone of its natural ligands.
For this reason, target identification must be followedby target validation, which confirms the likelihoodthat interfering with the target protein will impact onthe disease.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 18/75
Drug targets Drugs are substances that exert some kind of
physiological or biochemical effect on our bodies.They may be single compounds or mixtures, and theireffects may be beneficial or harmful.
All drugs interact with specific targets, which areusually proteins but in some cases DNA or RNA.
Drugs work either by stimulating or blocking the
activity of their targets.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 19/75
For the past decade, the number of molecular targets
for approved drugs has been debated. Surprisingly, for an industry that spends in excess of
US$50 billion on research and development each year,there is a lack of knowledge of the set of molecular
targets that the modern pharmacopoeia acts on. If we are to develop predictive methods to identify
potential new drug targets, it is essential that weestablish with confidence the number, characteristics
and biological diversity of targets of approved drugs.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 20/75
Number of drug targets Based on the mapping of the human genome in 2002 an
estimated 8000 targets were identified In 2006 Wishart et al reported 6,000 targets on the Drug
Data Base Website- only a small part of these relates to approved drugs
In 2003 Golden proposed that all then approved drugsacted through 273 proteins
In 2006 Zheng et al disclose 268 successful targets inTherapeutics Target Database and Imming etal cataloged218 targets for approved drugs
A consensus of 324 drug targets for all classes of approvedtherapeutic drugs was proposed by Overington et al: 266are HGD-proteins and 58 bacterial, viral, fungal or otherorganism targets.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 21/75
What accounts for the discrepancies?
Criteria chosen by the authors
- to include or not drugs under clinical trials but not yet approved
- considering or not multiple relevant targets for aunique drug including isoenzymes or differentmembers of a receptor family
Overington’s study
Identifies 21,000 marketed drugs (US) , of these 1,357 areunique drugs, 1,204 are small molecules (incl 192prodrug) and 166 are biological drugs
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 22/75
Overington’s study (2006)
27% binds to G-protein-coupled receptor 13% to nuclear receptors
7.9% to ligands-gated ion channels
5.5% to voltage-gated ion chanels
A selected target may have a unique approved drug or alarge number of “me-too” molecules
Imming etal study
218 listed targets: 66 human enzymes, 20 bacterial, viral andfungal or parasital enzymes; 20 families of GPCR; 12 nuclearreceptors, 7 cytokine receptors and about 10 ion channels and 10transport proteins of the plasma membrane
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 24/75
Conclusions from these studies Confirm that a very large number of putative drug targets
remains to be explored.
The introduction of genomics, proteomics and
metabolomics has paved the way for biology-drivenprocess, leading to plethora of drug targets.
The list of potential drug targets encoded in a genomeincludes most natural choice of virulent genes and species-
specific genes. Other options include targeting RNA, enzymes of the
intermediary metabolism, systems for DNA replication,translation apparatus or repair and membrane proteins
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 25/75
Biochemical classes of drug targets
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 27/75
Nucleic acid as drug targets Nucleic acids are the repository of genetic information.
DNA itself has been shown to be the receptor for many drugs used in cancer and other diseases.
These work through a variety of mechanisms includingchemical modification and cross linking of DNA (cisplatin) or cleavage of the DNA (bleomycin).
Much work either by intercalation of a polyaromatic
ring system into the double stranded helix(actinomycin D, ethidium) or by binding to the majorand minor grooves of DNA (e.g., netropsin) has beenreported.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 28/75
DNA has been shown to bethe target for
chemotherapy with effortsto design sequence-specificreagents for gene therapy.
Netropsin molecule. Thenarrowness of the groove
forces the netropsinmolecule to sitsymmetrically in thecenter, with its two pyrrolerings slightly non-coplanarso that each ring is parallelto the walls of itsrespective region of thegroove
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 29/75
RNA as drug target Recent advances in the determination of RNA structure
and function have led to new opportunities that will have asignificant impact on the pharmaceutical industry.
RNA, which, among other functions, serves as a messengerbetween DNA and proteins, was thought to be an entirely flexible molecule without significant structural complexity.However, recent studies have revealed a surprising intricacy
in RNA structure. This observation unlocks opportunities for the
pharmaceutical industry to target RNA with smallmolecules.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 30/75
Drugs that bind to RNA might produce effects thatcannot be achieved by drugs that bind to proteins.
Proof of the principle has already been provided by
success of several classes of drugs obtained fromnatural sources that bind to RNA or RNA-proteincomplexes.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 31/75
Membranes as drug targets Membranes are significant structural elements, both in
defining the boundaries of a cell as well as providinginterior compartments within the cell associated with
particular functions. Cell membranes themselves can also act as targets for
molecular recognition.
An understanding of the structural and dynamic functions
of the membranes (e.g., plasma membranes andintercellular membranes) may add to a more rationaldesign of drug molecules with improved permeationcharacteristics or specific membrane effects.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 32/75
Many general anesthetics are believed to work by theirphysical effects when dissolved in membranes.
Several classes of antibiotics like gramicidin A,antifungals like alamethicin and toxins such as
mellitin found in bee venoms have direct effects onplanar lipid bilayers, causing transmembrane pores.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 33/75
Proteins as drug targets Proteins continue to assume significant attention from
the pharmaceutical and biotechnology industries as a valuable source of potential drug targets.
Proteins provide the critical link between genes anddisease, and as such are the key to the understandingof basic biological processes including diseasepathology, diagnosis, and treatment.
Researchers have discovered many potentialtherapeutic targets, and there are currently more than700 products in various phases of development.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 34/75
However, translating the study of proteins into validated drug targets poses substantial challenges.Genome sequences instruct cells on how and when tomake proteins.
The proteins in turn are the active players in the cell.Proteins form the machinery of cells, allow cells tocommunicate, and can control growth or death of anorganism.
Because of their role in cells, most of the drug targetsare proteins.
Drugs work by binding specifically to a protein.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 35/75
Small molecules such as drugs, insecticides orherbicides usually exert their effects by binding toprotein targets.
In the past, many of these molecules were foundempirically with little or no knowledge of the
mechanism of action involved. In many cases, the targets that are modified by these
substances were identified in retrospect.
Interestingly, the majority of drugs currently in use
modulate either enzymes or receptors, most of themG-protein-coupled receptors.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 36/75
A. Enzymes
The macromolecule responsible for the catalysis of biochemical reactions are an obvious target when adisease state is associated with production of a
biologically active species. Enzymes are a classic target for therapeutic
intervention and numerous well-studied examplesexist.
Traditional medicinal chemistry enzyme targetsinclude kinases, phosphodiesterases, proteases andphosphotases.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 38/75
B. Receptor proteins G-protein–coupled receptors are a super family of seven
transmembrane spanning proteins that are activated by a wide range of extracellular ligands and are expressed in virtually all tissues.
Signaling through these receptors regulates a wide variety of physiological processes such as neurotransmission,chemotaxis, inflammation, cell proliferation, cardiac andsmooth muscle contraction as well as visual andchemosensory perception.
In view of their widespread distribution and importance inhealth and disease, it is not surprising that GPCRs are themost successful class of target proteins for drug discovery research.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 40/75
Some currently marketed drugs that target
GPCRsGPCR Indication(s) Drug(s)
Histamine Allergies, ulcers Cimetidine,Ranitidine,Terfenadine
β-adrenergic Hypertension, asthma Atenolol, Albuterol, Salmeterol
α -adrenergic Benign prostatichypertrophy
Terazosin , doxazosin
Dopamine Psychosis, Parkinson's Aripiprazole, Ropinerole
Serotonin Migraine, anxiety Zolmitriptan, clozapine, buspirone
Opiod Pain Butarphanol
Angiotensin Hypertension Losartan, Eprosartan
Muscarinic acetylcoline Alzheimer' s disease Bethanechol, dicyclomine
Leukotriene Asthma Pranlukast
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 41/75
The goal in developing drugs against the targets listedabove is often to modulate the function of the humanprotein while the goal in developing drugs againstpathogenic organisms is total inhibition, leading tothe death of the pathogen.
Antimicrobial drugs should be essential to thepathogen, have a unique function in the pathogen, bepresent only in the pathogen, and be able to beinhibited by a small molecule.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 42/75
The target should be essential, in that it is a part of acrucial cycle in the cell, and its elimination should leadto the pathogen's death.
The target should be unique: no other pathway shouldbe able to supplement the function of the target and
overcome the presence of the inhibitor. If the macromolecule satisfies all the outlined criteria
to be a drug target but functions in healthy humancells as well as in a pathogen, specificity can often be
engineered into the inhibitor by exploiting structuralor biochemical differences between the pathogenicand human forms.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 43/75
Finally, the target molecule should be capable of inhibition by binding of a small molecule.
Enzymes are often excellent drug targets becausecompounds are designed to fit within the active sitepocket.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 44/75
Protein as drug
targets
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 45/75
Drug action at proteins Types of proteins which drug interacts
a. Carrier proteinsb. Structural proteins
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 46/75
Carrier proteins Cell’s “smugglers” – smuggling the important
chemical building blocks of amino acids, sugars, andnucleic acids across the cell membrane such that the
cell can synthesize it’s proteins, carbohydrates andnucleic acids
Also transmit important neurotransmitters back intothe nerve that release them to limit its activity.
Carrier proteins are not identical; specific carriers fordifferent molecules that need to be carried acrossmembranes
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 47/75
Carrier proteins
Have recognition site that allows them to bind andencapsulate their specific cargo
Some carrier proteins can be fooled and it is possibleto design drugs that are mistaken as the usual cargo
molecules: carries it across membrane into the cell Carrier proteins can be viewed as drug targets when
drugs prevent them from functioning properly: drugstightly bound to the carrier once stowed away they
remain permanent lodgers- function of carrier is blocked
Example: cocaine and TCA: prevent neurotransmitter i.e.Noradrenaline from reentering nerve cells
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 49/75
Structural proteins Structural proteins do not normally act as drug targets
except tubulin
Tubulin molecules polymerize to fom small tubescalled microtubules in the cytoplasm
Microtubules function:
- maintenance of shape
- exocytosis, and- release of neurotansmitters
- Also involved in the mobility of cells
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 52/75
Function
Inflammatory cells called neutrophils are moble cells which normally protects the body against infection
They can also enter joints leading to inflammation and
arthritis One way of treatment is with colchicine which binds
to tubulin and causes the microtubules todepolymerize
Once mictotubules are broken down neutrophils losesmobility and can no longer migrate to the joints
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 55/75
Structure based drug design Drug discovery referred to, as ‘rational’ did not take
flight until the first structures of the targets weresolved.
In 1897, Ehrlich suggested a theory called the sidechain theory wherein he proposed that specific groupson the cells combine with the toxin.
Ehrlich coined these side chains as receptors.
Structure-based drug design of protein ligands hasemerged as a new tool in medicinal chemistry.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 56/75
The central assumption
of structure-based drugdesign is an iterativeone as shown in theright and often
proceeds throughmultiple cycles beforean optimized lead goesinto clinical trials.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 57/75
The first cycle includes the cloning, purification andstructure determination of the target protein ornucleic acid by one of three principal methods: X-ray crystallography, NMR or comparative modeling.
Using computer algorithms, compounds or fragmentsof compounds from a database are positioned into aselected region of the structure.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 58/75
These compounds are scored and ranked based on their
steric and electrostatic interactions with the target site andthe best compounds are tested further with biochemicalassays.
In the second cycle, structure determination of the targetin complex with a promising lead from the first cycle, one
with at least micromolar inhibition in vitro, reveals sites onthe compound that can be optimized to increase potency.
Additional cycles include synthesis of the optimized lead,structure determination of the new target: lead complex,and further optimization of the lead compound.
After several cycles of the drug design process, theoptimized compounds usually show marked improvementin binding, and often, specificity for the target.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 59/75
Drug action Effects induced by the drug on the biological system
Steps:
a. Binding to cellular molecular target
b. Signaling events leading to a cellular response(secretion, contraction, metabolism)
c. Integration at the level of tissues and organs:corresponding to a modification of physiological
function ( digestion, motricity, cardiovascularprocesses)
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 60/75
Drug action Drugs act by increasing or decreasing normal function
but do not endow the organism with new functions.
Future direction: Gene therapy may soon challengethis principle it remains valid for the immediate future
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 62/75
Drug effects
3. Other mechanisms of drug action may occur atcellular sites and may involve macromolecularcomponents, but the biological effects produced are
non-specific consequences of the chemicalproperties of the drugs.
Example: Detergents, alcohol, oxidizing agents, phenolderivatives act by destroying the integrity of the cell
through disrupting the cellular constituents
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 64/75
Drug binding, affinity and selectivity
The receptor concept was formulated by Langley and
the term “ receptor” was proposed by Ehrlich.
The concept of target binding or “ receptor binding, ”
Corpora non agunt nisi fi xata (compounds do notact unless bound), has been subject to refinement butis still valid.
The term “ receptor” should be now restricted to the
target of endogenous mediators but is often extentedto the targets of exogenous compounds endowing various biochemical functions
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 65/75
Drug binding, affinity and selectivity
The various physicochemical interactions between a
ligand and the target cooperate to establish the targetdrug interaction:
1. Hydrophobic interactions plays an important role instabilizing the conformation of proteins and in theassociation of hydrophobic structure between the drugand its target.
2. Hydrogen bonding is strongly directional and hasconsiderable importance both in the maintaining thesecondary and tertiary structure of the target itself andin the target–drug interaction.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 66/75
3. Charge transfer complexes formed between electron
rich donor molecules and electron-deficient acceptorsare also often involved in drug–target interaction.
4. Ionic bonds are of importance in the actions of
ionizable drugs since they act across long distances;ionic bonds result from the electrostatic attraction thatoccurs between oppositely charged ions;
most targets have a number of ionizable groups (COO-
, -O-,NH3+ ) at physiological pH that are available forthe binding with charged drug
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 67/75
Covalent bonds resulting in the formation of a long
lasting complex are less important in drug–targetinteraction.
Although most drug–target interactions are readily
reversible, some drugs, such as anticancer nitrogenmustards and alkylating compounds form reactive
cationic intermediates (i.e. aziridinium ion) that can
react with electron donor groups on the target.
These chemical interactions are related to theaffinity of the drug for its target
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 68/75
Various ligands for a single drug target
Most of target types can be stimulated or inhibiteddepending of the ligand chosen.
This leads to opposite regulations of related cellular
functions.
Terms used to characterize these different ligand typesdiffer according to the biochemical nature of thetargets.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 69/75
Enzyme ligands more often lead to the inhibition of
the enzyme activity, binding the active site withcompetition with the substrate (competitive inhibitors)or to allosteric sites ( non-competitive inhibitors ).
Activation of an enzyme is more difficult to proceedunless giving or generating an excess of substrate orco-substrate.
However some drugs are known to activate enzymes by
direct binding, that is, forskolin for adenylyl cyclase
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 70/75
Membrane transporters and ion channels permeability
can be increased or decreased by direct binding of selected drugs termed openers and inhibitors (orblockers ), respectively.
However, such ligands are too often improperly referredto as agonists and antagonists.
Receptors of mediators are able to interact with a large
diversity of ligand types:
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 71/75
Agonists mimic the effects of endogenous mediators(neurotransmitters, hormones, cytokines …).
Thus, mediators are considered the endogenous, orphysiological, agonists of their receptors.
Some exceptions to this concept are now known, somecouples of mediators acting through the binding to a single
receptor with agonist or antagonist properties respectively,i.e. interleukin 1 and IRAP, RANK-L and OPG, MSH and AGRP.
Full agonists elicit a maximal response of the organism,usually similar to that of the mediator.
Partial agonists elicit a partial response of the organism,and prevent the binding of the mediator. Thus the relatedfunction of the organism is decreased.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 72/75
Neutral antagonists prevent the binding of the mediator
and thus abolish downstream signaling biochemical
events and physiological responses.
Most neutral antagonists bind to the agonist bindingsite.
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 74/75
Receptors of mediators including an intrinsic ion
channels (ligand-gated ion channels such as nicotinicreceptors), or an enzyme activity (i.e. a tyrosine kinaseactivity such as insulin receptors, or ganylyl cyclaseactivity such as ANF receptors) have ligands for their
receptor part (agonists and antagonists) as well as fortheir ion channel (openers and inhibitors or blockers)or enzyme part (inhibitors).
8/4/2019 Molecular Drug Targets-1
http://slidepdf.com/reader/full/molecular-drug-targets-1 75/75
The activity of these various target types can also be
modulated indirectly through intracellular signaling,for instance by phosphorylation elicited by proteinkinases or dephosphorylation involving proteinphosphatases, or by protein–protein interactions such
as regulations induced by interaction with thecalciprotein calmoduline.
This offers large alternatives to modify the status of aputative target through indirect ways when directtargeting has been unsuccessful.